An independent research funded by Novo Nordisk, by scientists at the University of Leeds, shows marked weight loss among clinically obese individuals with a semaglutide type 2 diabetes (T2D) drug. This drug is similar to naturally-occurring hormone GLP-1 in the body, which targets sensory receptors of appetite control mechanism (in the hypothalamus portion of the brain) to reduce hungriness, moreishness or food cravings. Novo Nordisk makes semaglutide drug with a brand name Ozempic.
Scientists have conducted a study with a weekly dose semaglutide drug among 28 obese or overweight people with a body mass index (BMI) between 30 to 45 kg/m2. At the end of 12 weeks study, they found an average 24 percent reduction in their daily energy intake with semaglutide drug. In those experiments, the semaglutide drug demonstrated better control over appetite. People under this treatment preferred smaller meals and their preference to foods with high-fat content has been reduced. Scientists have successfully reduced 5 kg or 11 lbs of weight, mostly body fat, over a period of 12 weeks with semaglutide drug.
Once in a week, semaglutide injection costs about $676 per prescription. The oral form of the drug is under development. This drug is going to compete with other GLP-1 drugs in the market, dulaglutide from Trulicity and bydureon from AstraZeneca. FDA has approved Novo Nordisk's semaglutide drug on December 5, 2017.
Lead authors of the study were Professor John Blundell, Psycho-Biology (Biological Psychology), the University of Leeds, United Kingdom. The study findings were published on May 5, 2017, in the journal Diabetes, Obesity and Metabolism. Title of the article was "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity."
Moreishness : Preferring particular foods having high-fat content.
Doctors at the London hospital are conducting a radical treatment procedure to patients with type 2 diabetes (T2D) to prevent further worsening of the condition, reduce medical expenses and to reduce the need for medicines and insulin injection requirements. The first procedure was conducted at the University College Hospital (UCH), Bloomsbury, London, UK.
This procedure was not intended to cure type 2 diabetes (T2D). This procedure takes less than 60 minutes for completion. This procedure involves brief insertion of a tiny hot water bottle into the upper intestine via the mouth, stomach and duodenum. The duodenum lining tissue will be removed from the hot water balloon, which is at 90°C, causing the release of insulin to control blood sugar levels.
Patients with polycystic ovary syndrome (PCOS) or non-alcohol-related fatty liver disease (NAFLD) may also be benefited by this treatment. Dr. Rehan Haidry, a gastroenterologist, is leading a team of doctors in conducting the trials at the University College Hospital (UCH), Bloomsbury, London, UK. Contact cormac[dot]magee[at]nhs[dot]net to participate in the trial.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.